Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carotid Artery Stenting · 1 trial · 1 indication
A composite of major adverse events (MAE) including any death, any stroke and/or myocardial infarction occurring during the first 30 days post-procedure and ipsilateral stroke between 31 and 365 days post procedure.
| Arm | Type | Description |
|---|---|---|
| stent placement in the carotid artery | EXPERIMENTAL | placement of a bare metal stent for treatment of carotid artery stenosis |
| Name | Type | Description |
|---|---|---|
| Carotid Artery Stenting | DEVICE | placement of a bare metal stent at sites of stenosis in the carotid artery |
Inclusion Criteria: * The patient has a symptomatic or asymptomatic carotid artery stenosis that meets one of the following criteria: * Symptomatic: \> than or = to 50% carotid stenosis by angiography and a history of non-disabling stroke, transient ischemic attack (TIA) in the hemisphere suppli...
Carotid Artery Stenting is used for the treatment of Carotid Artery Stenosis, a condition characterized by narrowing of the carotid arteries. It is a minimally invasive procedure that involves placing a stent to open the artery and restore proper blood flow, potentially reducing the risk of stroke.
Carotid Artery Stenting is developed by Becton, Dickinson and Company, a global medical technology company. The company's stock is traded under the ticker symbol BDX on the New York Stock Exchange.
Carotid Artery Stenting is in Phase 3 clinical development. It is an investigational procedure and has not yet been approved by regulatory authorities. The Phase 3 trial, known as the ViVEXX Carotid Revascularization Trial (VIVA), has been completed.
Carotid Artery Stenting has one completed Phase 3 clinical trial, identified by the NCT number NCT00417963. This trial, titled 'ViVEXX Carotid Revascularization Trial (VIVA)', enrolled 407 participants with Carotid Artery Stenosis. The trial was uncontrolled and not randomized or double-blinded.
Carotid Artery Stenting is the procedure evaluated in the ViVEXX Carotid Revascularization Trial (VIVA). The trial, with NCT number NCT00417963, assessed the safety and efficacy of carotid artery stenting in patients with carotid artery stenosis.